Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 2/20 | 0.44 |
| ▸ | FBP1 | P09467 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | VDR | P11473 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RGS12 | O14924 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17186518 | 0.99 | PNP (0.44) | PNPFBP1ALDH1A1SMN1; SMN2HIF1A | |
| SCHEMBL18247 | 0.86 | PNP (0.59) | PNPALDH1A1KDM4EMEN1RGS12 | |
| SCHEMBL1980958 | 0.85 | PNP (0.57) | PNPALDH1A1KDM4EMEN1RGS12 | |
| SCHEMBL8145515 | 0.83 | KMT2A (0.48) | PNPSMN1; SMN2KMT2ATLR7 | |
| SCHEMBL17186356 | 0.83 | PNP (0.39) | PNPSMN1; SMN2USP2TLR7 | |
| Hydrochloric Acid SCHEMBL17186508 | 0.83 | PNP (0.47) | PNPKDM4EMEN1KMT2ATLR7 | |
| SCHEMBL1262618 | 0.83 | PNP (0.45) | PNPALDH1A1KDM4EMEN1RGS12 | |
| SCHEMBL3308556 | 0.83 | PNP (0.45) | PNPALDH1A1SMN1; SMN2KDM4ETLR7 | |
| SCHEMBL9234445 | 0.82 | PNP (0.44) | PNPALDH1A1KDM4EMEN1POLB | |
| Hydrochloric Acid SCHEMBL17186369 | 0.82 | PNP (0.39) | PNPSMN1; SMN2USP2TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | claimed |
| EP-3131877-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | Immunomet Therapeutics Inc. (US) | 2017-02-22 | — | — | EP | claimed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | claimed |
| JP-4054057-B2 | — | — | 2008-02-27 | — | — | JP | claimed |
| EP-0702683-B1 | 06-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER REC TECH LTD (GB) | 2003-09-17 | — | — | EP | claimed |
| WO-1994029312-A1 | O6-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1994-12-22 | — | — | WO | claimed |
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| EP-3131877-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | Immunomet Therapeutics Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | disclosed |
| EP-0702683-B8 | 06-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER REC TECH LTD (GB) | 2004-09-08 | — | — | EP | disclosed |
| EP-0702683-A1 | 06-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-03-27 | — | — | EP | disclosed |
| WO-1994029312-A1 | O6-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | PC, TFAM, PCK2 | PNP 292/4885FBP1 1883/4885ALDH1A1 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.